HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) Data Supplement Correspondence: Submit a response Alert me when this article is cited Alert me when Correspondence are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Sorensen, P. S. Articles by Bendtzen, K. Search for Related Content PubMed PubMed Citation Articles by Sorensen, P. S. Articles by Bendtzen, K. Related Collections All Immunology Autoimmune diseases Multiple sclerosis

Neutralizing antibodies hamper IFNß bioactivity and treatment effect on MRI in patients with MS

From the Danish Multiple Sclerosis Research Center (P.S.S., T.T., M.R.), Department of Neurology, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark; Danish Research Centre for Magnetic Resonance (H.K.M., A.R.L.), Copenhagen University Hospital Hvidovre, Denmark; and Institute for Inflammation Research (C.R., K.B.), Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark

Address correspondence and reprint requests to Dr. Per Soelberg Sorensen, Danish Multiple Sclerosis Research Center, Department of Neurology 2082, Rigshospitalet, DK-2100 Copenhagen, Denmark; e-mail: pss{at}rh.dk

We measured neutralizing antibodies (NABs) and the in vivo biologic response to interferon-ß on neopterin and ß₂-microglobulin blood levels. All NAB-negative patients had an in vivo biologic response (full or partial), whereas all high-level positive patients had no response. High-level NAB patients had more MRI activity than NAB-negative patients (p = 0.031). Patients with a full response had less MRI activity than patients without biologic response (p = 0.032).

Additional material related to this article can be found on the Neurology Web site. Go to www.neurology.org and scroll down the Table of Contents for the November 14 issue to find the title link for this article.

Disclosure: Dr. Soelberg Sorensen has received honoraria for lecturing, advisory councils, and expert testimony and financial support for his department from Biogen, Schering, Serono, Teva, Bayer, and Baxter; Dr. Tscherning has nothing to declare; Dr. Mathiesen has nothing to declare; Dr. Langkilde has nothing to declare; Dr. Ross has nothing to declare; Dr. Ravnborg has received honoraria for lecturing and research grants for his department from Sanofi Aventis, Schering, and Biogen; Dr. Bendtzen has received honoraria for expert testimony.

Received January 30, 2006. Accepted in final form July 10, 2006.

This article has been cited by other articles:

				P. Soelberg Sorensen Review: Neutralizing antibodies against interferon-beta Therapeutic Advances in Neurological Disorders, September 1, 2008; 1(2): 125 - 141. [Abstract] [PDF]

				P. Sorensen, N Koch-Henriksen, E. Flachs, and K Bendtzen Is the treatment effect of IFN-{beta} restored after the disappearance of neutralizing antibodies? Multiple Sclerosis, July 1, 2008; 14(6): 837 - 842. [Abstract] [PDF]

				C Gneiss, M Brugger, A Millonig, A Fogdell-Hahn, D Rudzki, J Hillert, T Berger, M Reindl, and F Deisenhammer Comparative study of four different assays for the detection of binding antibodies against interferon-{beta} Multiple Sclerosis, July 1, 2008; 14(6): 830 - 836. [Abstract] [PDF]

				R. M. Ransohoff Natalizumab for Multiple Sclerosis N. Engl. J. Med., June 21, 2007; 356(25): 2622 - 2629. [Full Text] [PDF]

				J. Oger and E. Gibbs Binding antibodies: Vancouver's perspective Multiple Sclerosis, May 1, 2007; 13(1_suppl): 36 - 43. [Abstract] [PDF]